LiDCO Group Plc Appointment of Head of North America
January 10 2017 - 2:00AM
RNS Non-Regulatory
TIDMLID
LiDCO Group Plc
10 January 2017
LIDCO GROUP PLC
("LiDCO" or the "Company" or the "Group")
Appointment of Head of North America
LiDCO (AIM: LID), the hemodynamic monitoring company, announces
the appointment of Shane Doorish, as Head of North America, with
immediate effect.
Shane brings with him 19 years of experience in the healthcare
sector having originally trained as a critical care nurse. This
includes 12 years with Edwards Lifesciences, a major global
provider of hemodynamic monitoring, where Shane held a number of
sales and marketing positions. Shane's last role with Edwards
Lifesciences was as Managing Director of Canada. Importantly for
LiDCO, Shane has an in depth knowledge of the hemodynamic market
and is well placed to be able to drive the Company's expansion
plans in North America.
In December 2016, LiDCO announced that it had raised gross funds
of GBP3.0 million, through a Placing and Subscription, to provide
growth capital to enable the Company to expand its global sales
team and undertake a more extensive and focused marketing
effort.
Commenting on the appointment, Matt Sassone, Chief Executive
Officer of LiDCO, said: "I am very pleased to have Shane joining
the team, this is an important step in our expansion plans for
North America. His knowledge of the market and commercial skills
are ideal to execute on LiDCO's plans to drive greater revenues
from the world's largest hemodynamic market."
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749 1500
Paul Clifford (Finance
Director)
finnCap Ltd Tel: +44 (0)20 7600 1658
Geoff Nash / Emily Watts
(Corporate Finance)
Stephen Norcross (Corporate
Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, developed at St Thomas' Hospital in London, has been
shown to significantly reduce morbidity and complications, length
of stay and overall costs associated with major surgery.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview: an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS(TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUKVBRBAAARAR
(END) Dow Jones Newswires
January 10, 2017 02:00 ET (07:00 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024